Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.

[1]  C. Brightling,et al.  Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. , 2018, The Lancet. Respiratory medicine.

[2]  C. Brightling,et al.  Asthma , 2018, The Lancet.

[3]  C. Brightling,et al.  New and emerging drug treatments for severe asthma , 2018, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  Richard Beasley,et al.  After asthma: redefining airways diseases , 2017, The Lancet.

[5]  J. Corren,et al.  Tezepelumab in Adults with Uncontrolled Asthma , 2017, The New England journal of medicine.

[6]  E. Bleecker,et al.  Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial , 2016, The Lancet.

[7]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[8]  E. Bateman,et al.  Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. , 2016, The Lancet. Respiratory medicine.

[9]  I. Pavord,et al.  Fevipiprant, a prostaglandin D2 receptor 2 antagonist, in patients with persistent eosinophilic asthma: a single-centre, randomised, double-blind, parallel-group, placebo-controlled trial. , 2016, The Lancet. Respiratory medicine.

[10]  E. R. Sutherland,et al.  Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial , 2016, The Lancet.

[11]  M. Braddock,et al.  Effect of Anti-IL-13 Treatment on Airway Dimensions in Severe Asthma. , 2016, American journal of respiratory and critical care medicine.

[12]  A. Sousa,et al.  Relationship between lung function and quantitative computed tomographic parameters of airway remodeling, air trapping, and emphysema in patients with asthma and chronic obstructive pulmonary disease: A single-center study , 2016, The Journal of allergy and clinical immunology.

[13]  M. Weatherall,et al.  Serum periostin in obstructive airways disease , 2016, European Respiratory Journal.

[14]  C. Brightling,et al.  Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease , 2016, Therapeutic advances in chronic disease.

[15]  P. O'Byrne,et al.  Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. , 2015, The Lancet. Respiratory medicine.

[16]  E. Bateman,et al.  Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. , 2015, The Lancet. Respiratory medicine.

[17]  W. Busse,et al.  Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. , 2014, The Lancet. Respiratory medicine.

[18]  Ian D Pavord,et al.  Mepolizumab treatment in patients with severe eosinophilic asthma. , 2014, The New England journal of medicine.

[19]  E. Bleecker,et al.  International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma , 2013, European Respiratory Journal.

[20]  W. Busse,et al.  Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. , 2013, The Journal of allergy and clinical immunology.

[21]  C. Brightling,et al.  A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma , 2012, European Respiratory Journal.

[22]  Ella A. Kazerooni,et al.  CT-based Biomarker Provides Unique Signature for Diagnosis of COPD Phenotypes and Disease Progression , 2012, Nature Medicine.

[23]  C. Brightling,et al.  Clinical management and outcome of refractory asthma in the UK from the British Thoracic Society Difficult Asthma Registry , 2012, Thorax.

[24]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[25]  C. Brightling,et al.  Interleukin‐13: prospects for new treatments , 2009, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[26]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[27]  I. Pavord,et al.  Comparison of asthma treatment given in addition to inhaled corticosteroids on airway inflammation and responsiveness , 2006, European Respiratory Journal.

[28]  R. Puri,et al.  IL-13 signaling through the IL-13α2 receptor is involved in induction of TGF-β1 production and fibrosis , 2006, Nature Medicine.

[29]  R. Panettieri,et al.  IL‐13 enhances agonist‐evoked calcium signals and contractile responses in airway smooth muscle , 2003, British journal of pharmacology.

[30]  A. Kay,et al.  Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.

[31]  J. Kinet,et al.  Direct effects of interleukin-13 on signaling pathways for physiological responses in cultured human airway smooth muscle cells. , 2001, American Journal of Respiratory and Critical Care Medicine.

[32]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .